This company operates_as a biotechnology company focused_on_developing and commercializing monoclonal antibody - based therapies for the treatment of CAUSE_OF_DEATH. It was_incorporated in DATE. The company is headquartered in CITY,_STATE_OR_PROVINCE, COUNTRY COUNTRY. It is the largest global oncology biotechnology company based in the LOCATION_LOCATION. It is focused_on_developing and commercializing a new generation of targeted, empowered antibody - based therapies that have the potential to change the foundation of treatment for people with CAUSE_OF_DEATH. The company 's industry - leading antibody - drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative TITLE systems, and the power of potent cell - killing agents to_treat CAUSE_OF_DEATH. Using its proprietary technology, it is able_to optimize each ORGANIZATION to potentially improve outcomes for patients. ORGANIZATION are an_integral_part of the evolving CAUSE_OF_DEATH treatment paradigm with their specificity, stability and potency. It has NUMBER marketed product, ADCETRIS (brentuximab vedotin), which is the ORDINAL in a new class of ADCs, commercially available in more_than_NUMBER_countries worldwide for relapsed classical PERSON CAUSE_OF_DEATH (HL) and relapsed systemic anaplastic large cell CAUSE_OF_DEATH (sALCL). It also is advancing a strong pipeline of innovative therapies for blood cancers and solid tumors, including enfortumab vedotin (ASG - 22ME) for urothelial CAUSE_OF_DEATH under its collaboration_with Astellas, and SGN - LIV1A for triple - negative CAUSE_OF_DEATH_CAUSE_OF_DEATH. Its programs are_designed to address significant unmet_medical needs and to improve treatment outcomes for patients. The company is committed_to improving the lives of people with CAUSE_OF_DEATH through innovative and empowered antibody - based therapies.